预约演示
更新于：2026-02-26
Fluorometholone
氟米龙
更新于：2026-02-26
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1972-01-12), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H29FO4 |
InChIKeyFAOZLTXFLGPHNG-KNAQIMQKSA-N |
CAS号426-13-1 |
关联
27
项与 氟米龙 相关的临床试验NCT07308938
Trial of Topical Fluorometholone as Adjunctive Therapy for Bacterial Corneal Ulcers
ChiCTR2500114387
The Role of Corneal Densitometry and Tear Cytokine Profiling in Personalizing Post-FS-LASIK Pharmacotherapy
NCT06498440
Comparative Efficacy of NSAID and Steroid-NSAID Combination Following Selective Laser Trabeculoplasty: a Phase 4, Single-centre, Randomized Controlled Trial
100 项与 氟米龙 相关的临床结果
登录后查看更多信息
100 项与 氟米龙 相关的转化医学
登录后查看更多信息
100 项与 氟米龙 相关的专利（医药）
登录后查看更多信息
587
项与 氟米龙 相关的文献（医药）2026-03-01Lancet Global Health
Evaluation of fluorometholone as adjunctive medical therapy for trachomatous trichiasis surgery (FLAME): a parallel, double-blind, randomised controlled field trial in the Jimma Zone, Ethiopia
Article
作者: Burton, Matthew J ; McWilliams, Kathleen ; Megersa, Alemayehu ; Tulu, Berhanu ; Abdela, Genemo ; Bunya, Vatinee Y ; Mengesha, Aemero Abateneh ; Ying, Gui-Shuang ; Succar, Tony ; Mohammad, Gadisa ; Dodson, Sarity ; Cheru, Tolossa ; Gemechu, Alemu ; Mohammed, Ahlam Awad ; Abashawl, Aida ; Alemayehu, Wondu ; Kumsa, Dereje Adugna ; Kempen, John H ; Frick, K Davina ; Jin, Fangming ; Chen, Yineng ; Maguire, Maureen G
BACKGROUND:
In trachoma, trachomatous trichiasis mediates visual impairment. Trachomatous trichiasis surgery has an unacceptably high relapse incidence. We hypothesised that anti-inflammatory therapy with fluorometholone 0·1% suspension (hereafter fluorometholone) eyedrops perioperatively twice daily for 28 days would safely, efficaciously, and cost-effectively reduce postoperative trachomatous trichiasis relapse (PTT).
METHODS:
In this randomised, parallel, placebo-controlled trial, we compared placebo (artificial tears) with fluorometholone for eyes undergoing trachomatous trichiasis surgery in participants aged 15 years and older at rural health centres and post sites in the Jimma zone, Ethiopia. Participants were randomly allocated (1:1) to either placebo or fluorometholone. Treatment randomisation was stratified and blocked by surgeon. Participants, surgeons, and outcome assessors were masked to treatment assignment. Outcomes were evaluated at 4 weeks, 6 months, and 12 months postoperatively. The primary outcome was cumulative 12-month incidence of PTT, defined as any of: one or more lashes touching the globe; evidence of epilation; or occurrence of repeat trachomatous trichiasis surgery. This study is registered with ClinicalTrials.gov, NCT04149210.
FINDINGS:
Between Aug 19, 2021, and Nov 30, 2024, 2410 participants (1692 [70·2%] self-reported as female and 718 [29·8%] as male; 3235 eyes) were recruited. 1204 participants were randomly allocated to fluorometholone and 1206 to placebo. 823 (34·1%) participants had bilateral trachomatous trichiasis surgery. Baseline treatment group characteristics were similar; 1180 (98·0%) participants in the fluorometholone group and 1181 (97·9%) in the placebo group were evaluated at the 12-month timepoint. In the intention-to-treat analysis, the cumulative incidences of PTT during 12 months of follow-up were 218 (13·4%) of 1625 eyes in the placebo group and 213 (13·4%) of 1593 eyes in the fluorometholone group (95% CI for difference -2% to 2%). Prespecified secondary efficacy and safety outcomes were not statistically different between groups (all p≥0·10). The incidence of adverse events attributed to study treatment was nine (0·7%) in the placebo group and four (0·3%) in the fluorometholone group (p=0·17); satisfaction with surgery (satisfied or very satisfied) was recorded for 3156 (99·7%) of 3167 eyes. Health economic considerations did not favour programmatic use of fluorometholone given its inefficacy.
INTERPRETATION:
Fluorometholone twice daily for 4 weeks was safe but not efficacious or cost-effective for reducing PTT, and hence is not recommended for programmatic use.
FUNDING:
National Eye Institute (National Institutes of Health) and AbbVie.
TRANSLATIONS:
For the Amharic and Oromifa translations of the abstract see Supplementary Materials section.
2026-02-01EXPERIMENTAL EYE RESEARCH
Tacrolimus exerts anti-inflammatory effects in moderate to severe dry eye through activation of autophagy-lysosomal pathway
Article
作者: Jia, Zhe ; Guo, Qian ; Yang, Ruibo ; Zhao, Shaozhen ; Liu, Hui ; Zhang, Chen ; Zhang, Zijie ; Lu, Xiaoxiao ; Huang, Yue ; Ma, Yunjing
This study aimed to investigate the therapeutic potential and anti-inflammatory mechanisms of tacrolimus (FK506) in moderate to severe dry eye by clinical, in vivo, and in vitro studies. We evaluated the effect of 0.1 % FK506 versus 0.1 % fluorometholone eye drops on patients with moderate to severe dry eye. Ocular surface disease index questionnaire (OSDI), tear breakup time (TBUT), corneal erosion, Schirmer's I test, and conjunctival impression cytology were measured at 2, 4, and 8 weeks. Tear samples from patients before and after FK506 treatment were subjected to proteomic analysis. The underlying mechanisms of FK506 were clarified using dry eye rat model and hypertonic-stimulated human corneal epithelial cells. Results demonstrated that FK506 showed transiently superior efficacy over fluorometholone in OSDI at week 2 (P = 0.041) and TBUT at week 4 (P = 0.001), despite both groups achieving significant improvements in all parameters from baseline to week 8 (P < 0.001). Tear proteomics revealed FK506-mediated modulation of autophagy-lysosomal pathway. FK506 improved ocular surface damage, reduced TNF-α and IL-1β, and upregulated LC3B II, TFEB, and LAMP1 protein expression, accompanied by reduced P62 in the rat cornea. In vitro, FK506 suppressed pro-inflammatory cytokines via enhanced autophagic flux, promoted TFEB nuclear translocation, restored lysosomal structural and functional integrity, while inhibited mTOR phosphorylation. Knockdown of TFEB reversed the FK506-mediated benefits. Overall, FK506 alleviates the symptoms and signs of moderate to severe dry eye by suppressing the inflammatory response in corneal epithelial cells. This therapeutic effect is mediated through the activation of the TFEB-driven autophagy-lysosomal pathway.
2026-01-01Retinal cases & brief reports
REDUCTION OF SCLERAL THICKNESS WITH TOPICAL FLUOROMETHOLONE IN MANAGEMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY COMPLICATED BY POSTERIOR CYSTOID DEGENERATION
Article
作者: Kulikov, Alexei N. ; Vasiliev, Alexander S. ; Kalinicheva, Yana A. ; Chhablani, Jay ; Maltsev, Dmitrii S.
Purpose::
To describe the role of topical fluorometholone in the treatment of eyes with central serous chorioretinopathy complicated by posterior cystoid degeneration.
Methods::
Patients with posterior cystoid degeneration associated with central serous chorioretinopathy were prospectively recruited, examined with multimodal imaging, and prescribed for topical fluorometholone four times daily. Eyes with macular neovascularization were excluded based on optical coherence tomography angiography. Spectral-domain optical coherence tomography was used to monitor central retinal thickness, subfoveal choroidal thickness, and the thickness of the anterior sclera.
Results::
Five eyes of four patients were included. Intraretinal and subretinal fluid in all eyes had been unresponsive to all standard treatments, but improved remarkably or completely resolved with limited improvement of visual acuity after a mean of 6.0 ± 2.0 weeks of topical fluorometholone administration. In all cases, significant reduction of scleral thickness was observed with no or mild intraocular pressure rise.
Conclusion::
Severe cases of central serous chorioretinopathy complicated by posterior cystoid degeneration associated with vision loss may be managed with topical fluorometholone. The positive effects of steroids in central serous chorioretinopathy may be mediated by their effects on reduction of the scleral thickness.
100 项与 氟米龙 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部疾病 | 中国 | 1999-02-13 | |
| 皮肤疾病 | 中国 | 1999-02-13 | |
| 睑缘炎 | 日本 | 1975-10-01 | |
| 结膜炎 | 日本 | 1975-10-01 | |
| 虹膜睫状体炎 | 日本 | 1975-10-01 | |
| 虹膜炎 | 日本 | 1975-10-01 | |
| 角膜炎 | 日本 | 1975-10-01 | |
| 术后炎症 | 日本 | 1975-10-01 | |
| 巩膜炎 | 日本 | 1975-10-01 | |
| 葡萄膜炎 | 日本 | 1975-10-01 | |
| 炎症 | 美国 | 1972-01-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
Pubmed 人工标引  | 临床4期 | 111 | 範遞襯築遞艱鏇窪膚鹹(鏇繭選築衊憲顧憲夢壓) = 鏇窪窪獵淵鹹廠壓餘製 窪夢選壓鏇遞願衊窪衊 (窪餘鹽鹽醖積鹽顧鹽廠, 2.19) 更多 | 积极 | 2022-07-04 | ||
範遞襯築遞艱鏇窪膚鹹(鏇繭選築衊憲顧憲夢壓) = 壓餘鹽醖餘製願壓鏇範 窪夢選壓鏇遞願衊窪衊 (窪餘鹽鹽醖積鹽顧鹽廠, 8.46) 更多 | |||||||
临床4期 | 72 | 淵選蓋製鏇鏇餘憲蓋鑰(觸製觸鏇構遞遞壓艱鹹) = 簾襯膚積襯淵齋蓋艱鹹 鬱糧襯觸構構餘衊範築 (築蓋網構製網壓繭觸餘 ) 更多 | - | 2020-11-16 | |||
CSA 0.5% eye drops | 淵選蓋製鏇鏇餘憲蓋鑰(觸製觸鏇構遞遞壓艱鹹) = 蓋艱構糧壓鏇餘齋醖餘 鬱糧襯觸構構餘衊範築 (築蓋網構製網壓繭觸餘 ) 更多 | ||||||
临床2期 | 264 | (Fluorometholone 0.1% Solution) | 製選選餘襯遞鹽壓醖鹹 = 選製顧糧艱遞醖鹹願壓 憲觸範餘鑰獵製糧糧獵 (壓網鏇觸獵餘膚窪餘構, 窪壓鬱鹽齋網構網鏇壓 ~ 艱壓憲願襯範鹹鹽簾蓋) 更多 | - | 2014-08-25 | ||
(Prednisolone Acetate 1% Solution) | 製選選餘襯遞鹽壓醖鹹 = 壓選糧積衊鬱壓壓積鑰 憲觸範餘鑰獵製糧糧獵 (壓網鏇觸獵餘膚窪餘構, 壓繭淵遞遞憲選蓋鏇遞 ~ 繭簾網膚夢鑰願淵構願) 更多 | ||||||
临床3期 | - | 62 | Topical NSAID (ketorolac) | 鬱糧夢廠簾鹹廠顧糧壓(衊餘獵廠繭窪獵蓋夢襯) = 網廠艱夢醖窪製獵艱壓 襯願窪願夢窪簾繭鬱觸 (獵艱鹽糧繭選鏇遞鬱遞 ) 更多 | 积极 | 2009-04-01 | |
Topical steroid (fluorometholone) | 鬱糧夢廠簾鹹廠顧糧壓(衊餘獵廠繭窪獵蓋夢襯) = 積淵選製齋簾餘膚鑰積 襯願窪願夢窪簾繭鬱觸 (獵艱鹽糧繭選鏇遞鬱遞 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用